EcoDrugPlus

Cytochrome P450, Family 3, Subfamily A, Polypeptide 65

Ensembl ID : ENSOTSG00005047781
Gene Symbol: CYP3A65
1 Cross references
521 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A, Polypeptide 65

Ensembl ID : ENSOTSG00005047783
Gene Symbol: CYP3A65
1 Cross references
521 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A, Polypeptide 65

Ensembl ID : ENSOTSG00005017587
Gene Symbol: CYP3A65
1 Cross references
518 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A, Polypeptide 65

Ensembl ID : ENSOTSG00005047782
Gene Symbol: CYP3A65
1 Cross references
521 Possible Orthologues:

Cytochrome P450, Family 3, Subfamily A, Polypeptide 65

Ensembl ID : ENSOTSG00005007520
Gene Symbol: CYP3A65
1 Cross references
518 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSOTSG00005037164
Gene Symbol: LOC112234581
3 Cross references
207 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSOTSG00005005641
Gene Symbol: LOC112245346
3 Cross references
128 Possible Orthologues:

Delta-Type Opioid Receptor-Like

Ensembl ID : ENSOTSG00005037517
Gene Symbol: LOC112234581
3 Cross references
207 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1a

Ensembl ID : ENSOTSG00005014939
Gene Symbol: DGAT1A
1 Cross references
184 Possible Orthologues:

Diacylglycerol O-Acyltransferase 1a

Ensembl ID : ENSOTSG00005005748
Gene Symbol: DGAT1A
1 Cross references
184 Possible Orthologues:

Dihydroorotate Dehydrogenase

Ensembl ID : ENSOTSG00005005662
Gene Symbol: DHODH
1 Cross references
167 Possible Orthologues:

Dihydroorotate Dehydrogenase (Quinone), Mitochondrial-Like

Ensembl ID : ENSOTSG00005043185
Gene Symbol: LOC112235772
3 Cross references
166 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).